OneSource Q4 Revenue Up 47% on Semaglutide Launches

OneSource reported Q4 FY26 revenue of INR 4,282 million, a 47% sequential increase driven by the commercial launch of generic Semaglutide in India.
The company received approvals for its drug-device combinations in Canada and expects a US tentative approval, setting the stage for strong growth in FY27.
Capacity expansion is on track with a second production line undergoing qualification and expected to be available for commercialization in Q2 FY27.
Management reaffirmed its long-term FY28 guidance of US$400 million in organic revenue with approximately 40% EBITDA margins.